| Prader-Willi Syndrome | |
|---|---|
| Characteristic facial features: narrow forehead, almond-shaped eyes | |
| Also Known As | Prader-Willi-Labhart Syndrome, PWS |
| ICD-10 | Q87.1 |
| OMIM | 176270 |
| Inheritance | Autosomal dominant (imprinted); usually sporadic |
| Gene Region | 15q11.2-q13 (paternal allele) |
| Chromosome | 15q11.2 |
| Onset | Infancy (hypotonia); childhood (hyperphagia) |
| Key Features | Infantile hypotonia, hyperphagia, obesity, intellectual disability, behavioral problems |
| Prevalence | 1 in 10,000-30,000 |
| Treatment | Growth hormone, strict diet control, behavioral therapy |
Prader Willi Syndrome is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Prader-Willi Syndrome (PWS) is a rare genetic disorder caused by loss of function of genes on the paternal chromosome 15q11.2-q13 region [1]. The condition is characterized by a distinctive two-phase clinical presentation: infants present with severe hypotonia and feeding difficulties, while childhood onset brings hyperphagia (uncontrollable hunger) leading to severe obesity if not strictly managed [2].
First described by Swiss doctors Andrea Prader, Alexis Labhart, and Heinrich Willi in 1956, Prader-Willi syndrome affects approximately 1 in 10,000 to 1 in 30,000 individuals worldwide. The syndrome represents the most common known genetic cause of life-threatening obesity [1:1].
Prader-Willi syndrome provides another critical example of genomic imprinting in humans. The 15q11-q13 region contains multiple imprinted genes that are expressed in a parent-of-origin-specific manner:
Loss of the paternal allele results in Prader-Willi syndrome, while loss of the maternal allele causes Angelman syndrome (a related but distinct disorder) [3].
| Mechanism | Frequency | Description |
|---|---|---|
| Paternal 15q11-q13 deletion | ~70% | Microdeletion on paternal chromosome |
| Maternal uniparental disomy | ~25% | Two maternal copies of chromosome 15 |
| Imprinting center defect | ~3-5% | Epigenetic silencing of paternal alleles |
| Translocation | <1% | Rare chromosomal rearrangements |
The SNORD116 cluster of small nucleolar RNAs (snoRNAs) appears particularly important in driving the PWS phenotype, especially the hyperphagia and behavioral characteristics [4].
Neonatal Period
Characteristic Facial Features
Hyperphagia and Obesity
Neurocognitive Profile
Behavioral Manifestations
The clinical diagnosis involves recognition of the characteristic phenotype:
Confirmation requires genetic testing:
Management requires a team approach including:
Dietary Management
Growth Hormone Therapy
Behavioral Interventions
Medical Management
While primarily a neurodevelopmental disorder, Prader-Willi syndrome shares interesting features with neurodegenerative conditions:
Hypothalamic dysfunction: Both PWS and various neurodegenerative diseases involve hypothalamic dysfunction
Sleep disorders: High prevalence of sleep disturbances parallels findings in neurodegeneration
Mitochondrial dysfunction: Emerging evidence suggests mitochondrial abnormalities in PWS
Inflammatory processes: Some evidence of systemic inflammation in PWS
Studying PWS provides insights into:
Mouse models with paternal 15q11-q13 deletions recapitulate key features:
With early diagnosis and comprehensive management:
The study of Prader Willi Syndrome has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
This section highlights recent publications relevant to this disease.
Dampened surge in heart rate at respiratory event termination in children with Prader-Willi syndrome. ↩︎ ↩︎
Unravelling Narcolepsy: A Series of Complex Pediatric Cases. ↩︎
Functional Independence in Adults With Prader-Willi Syndrome: First Report Using the FIM Instrument. ↩︎
Circulating levels of ghrelin and hyperphagia in patients with rare genetic neurodevelopmental disorders. ↩︎